Molbio Diagnostics is a pioneering Indian in-vitro diagnostics (IVD) company with a global footprint. We have deep expertise in development, production, and commercialization of pathbreaking diagnostic platforms that address the clinical need gaps and are deployed at Point-of-Care (POC), resource-limited settings. Our flagship product, Truenat, has been successfully deployed across 85+ countries and has positively impacted millions of lives. Bigtec Labs is the R&D division of Molbio and functions as an innovation engine with a multidisciplinary team of 100 scientists and engineers, who excel in translating scientific ideas into market-ready products.

Following the successful completion of EDGE 2024, Molbio and Bigtec now bring EDGE 2.0, a pioneering scaleup partnership program for MedTech startups, for acceleration of product development and commercialization. Molbio and Bigtec are launching a global call to collaborate with MedTech startups and SMEs for acceleration of product development and commercialization. This is an intensive 12-week cohort program for understanding high impact technology acceleration and faster Go-To-Market (GTM) traction. At the end of this program, Molbio would engage with a few cohort participants for future partnerships. This would potentially involve bridge funding for product co-development, licensing, sales and distribution. Each cohort participant will receive bespoke guidance. The program will be conducted in hybrid mode and will involve intermittent visits to Bangalore and Goa. All expenses, including travel and stay, of the program will be borne by Molbio.